## Clinical Presentation: Severe Malaria This patient has **cerebral malaria** — a medical emergency with parasitemia >5%, altered consciousness, and CSF pleocytosis without bacterial infection. Mortality is 15–20% even with treatment. ## Why Artemether Is Correct **High-Yield:** Artemether (or artesunate) is the WHO-recommended first-line parenteral agent for severe malaria, including cerebral malaria, in all regions globally since 2011. **Key Point:** Artemether dosing for severe malaria: - Loading dose: 80 mg IM (or IV) stat - Maintenance: 80 mg IM (or IV) daily for minimum 3 days - Switch to oral artemisinin-based combination therapy (ACT) once patient can tolerate oral intake **Clinical Pearl:** Artemether has superior efficacy and faster parasite clearance than quinine. Studies show artemether reduces mortality by ~35% compared to quinine in severe malaria. ## Mechanism of Artemether Artemisinin derivatives are sesquiterpene lactones that generate reactive oxygen species (ROS) via interaction with heme iron. They rapidly kill all asexual parasite stages, including sequestered parasites in cerebral microvasculature. ## Why Other Agents Are Suboptimal | Agent | Why Not Ideal | |-------|---------------| | Chloroquine | P. falciparum is chloroquine-resistant in most endemic areas; chloroquine is slow-acting and unsuitable for cerebral malaria | | Quinine | Older parenteral option; slower parasite clearance; higher hypoglycemia and ototoxicity risk; artemether is superior | | Mefloquine | Oral agent; cannot be used in unconscious patient; slower onset than artemether | **Mnemonic:** **ARTEMIS** — Artemether/Artesunate Recommended Treatment for Emergency Malaria In Severe illness.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.